Dianthus Therapeutics Stock Current Valuation
| DNTH Stock | 19.49 0.95 4.65% |
Valuation analysis of Dianthus Therapeutics helps investors to measure Dianthus Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
Please note that Dianthus Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Dianthus Therapeutics is based on 3 months time horizon. Increasing Dianthus Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Dianthus Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Dianthus Stock. However, Dianthus Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.49 | Real 26.64 | Hype 19.56 | Naive 20.03 |
The intrinsic value of Dianthus Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Dianthus Therapeutics' stock price.
Estimating the potential upside or downside of Dianthus Therapeutics helps investors to forecast how Dianthus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dianthus Therapeutics more accurately as focusing exclusively on Dianthus Therapeutics' fundamentals will not take into account other important factors: Dianthus Therapeutics Company Current Valuation Analysis
Dianthus Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Dianthus Therapeutics Current Valuation | 387.71 M |
Most of Dianthus Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dianthus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Dianthus Therapeutics has a Current Valuation of 387.71 M. This is 97.3% lower than that of the Biotechnology sector and 91.65% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.67% higher than that of the company.
Dianthus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dianthus Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dianthus Therapeutics could also be used in its relative valuation, which is a method of valuing Dianthus Therapeutics by comparing valuation metrics of similar companies.Dianthus Therapeutics is currently under evaluation in current valuation category among its peers.
Dianthus Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (24.07) % | ||||
| Current Valuation | 387.71 M | ||||
| Shares Outstanding | 32.13 M | ||||
| Shares Owned By Insiders | 8.07 % | ||||
| Shares Owned By Institutions | 91.93 % | ||||
| Number Of Shares Shorted | 5.31 M | ||||
| Price To Book | 1.88 X | ||||
| Price To Sales | 105.31 X | ||||
| Revenue | 6.24 M | ||||
| Gross Profit | 6.24 M | ||||
| EBITDA | (101.86 M) | ||||
| Net Income | (84.97 M) | ||||
| Total Debt | 1.49 M | ||||
| Book Value Per Share | 11.33 X | ||||
| Cash Flow From Operations | (78.18 M) | ||||
| Short Ratio | 25.81 X | ||||
| Earnings Per Share | (2.55) X | ||||
| Target Price | 52.6 | ||||
| Number Of Employees | 78 | ||||
| Market Capitalization | 656.64 M | ||||
| Total Asset | 374.01 M | ||||
| Retained Earnings | (174.39 M) | ||||
| Working Capital | 262.45 M | ||||
| Net Asset | 374.01 M |
About Dianthus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dianthus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dianthus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dianthus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:Check out Dianthus Therapeutics Piotroski F Score and Dianthus Therapeutics Altman Z Score analysis. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.